Human Amniotic Fluid Supernatant as a Therapeutic Agent for Hyperproliferative and Inflammatory Skin Conditions.

Description:

Keratinocytes are a major cell type in the epidermis. However, keratin proliferation and dysregulation can lead to many keratin associated diseases or disorders, including hyperproliferative skin disorders such as psoriasis, eczema, and keratosis, scaring or suboptimal wound healing. Faculty members at the University of Texas Health Science Center at Houston have developed a novel method and composition for the treatment of keratin associated hyperproliferative conditions in mammals comprising of amniotic fluid, or purified derivatives thereof, that selectively inhibit keratinocyte proliferation by inducing differentiation.

 

Inventors:

Loveprett K. Mann

Ramesha Papanna

Jong Hak Won

 

Intellectual Property Status:

This technology has a pending patent application and is available for licensing.

 

 

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Biologics
Therapeutics
For Information, Contact:
Christine Flynn
Associate Director, Licensing and New Venture Development
University of Texas Health Science Center At Houston
Christine.Flynn@uth.tmc.edu
Inventors:
Keywords:
© 2020. All Rights Reserved. Powered by Inteum